// App-Quantinova.ai

P-80 : TRYbeCA-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma

Researchers

Presenter

  • P. Hammel

Principal Investigators

  • G. Creemers

  • E. Van Cutsem

  • A. Cubillo

  • R. Greil

  • H. Wasan

  • J. Metges

  • M. Noel

  • P. Nygren

  • P. Osterlund

  • T. Seufferlein

  • T. Macarulla

  • C. Fountzilas

  • A. Gupta

  • L. Grummer

  • S. Kacel

  • N. Biswas-Baldwin

  • R. Kay

  • H. Youssoufian

  • I. El-Hariry

  • M. Hidalgo

Medical Centers

  • Hopital Beaujon (AP-HP), Clichy, and University Paris VII, Paris, France

  • Medical Oncology Unit, Universita Politecnica delle Marche, Azienda Ospedaliero-Universitaria Ospedali Riuniti Umberto I - GM Lancisi - G Salesi, Ancona, Italy., ancona, Italy

  • Catharina hospital, Eindhoven, Netherlands

  • University Hospitals Leuven and KU Leuven, Leuven, Belgium

  • Hospital La Paz, Madrid, Spain

  • Paracelsus Medical University Salzburg, Salzburg, Austria

  • Hammersmith Hospital NHS Trust, London, United Kingdom

  • Institut de Cancérologie et D'hématologie Du CHRU, Brest, France

  • Georgetown University, Washington D.C., DC, United States

  • Akademiska sjukhuset, Uppsala,

  • Tampere and Helsinki University Hospitals and Universities, Tampere and Helsinki, Finland

  • Universitatsklinikum Ulm, Ulm, Germany

  • Vall d Hebron University Hospital (HUVH) and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain

  • Medicine,Roswell Park Comprehensive Cancer Center,Buffalo,United States

  • Erytech, Lyon, France

  • RK Statistics, Bakewell, United Kingdom

  • Weill Cornell Medical College, New York City, NY, United States

Locations

  • France

  • Italy

  • Netherlands

  • Belgium

  • Spain

  • Austria

  • United Kingdom

  • United States

  • Sweden

  • Finland

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Pancreatic cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • FOLFIRI

  • Irinotecan

  • 5-fluorouracil + leucovorin

  • Adrucil injection

  • Fluorouracil

  • L-leucovorin

  • Gemcitabine

  • leucovorin

  • ERY001

  • Protein-bound paclitaxel

Outcome

  • N/A

Study Design

  • Randomized

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved